Want to join the conversation?
$DGX's total net revenues for 2015 rose by 0.8% from the previous year. The contribution of its clinical trials testing business to the clinical trials central laboratory services joint venture, Q2 Solutions, negatively impacted total net revenues by 1.2%.
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.